HypertensionWay2TextNCT02778542
Bidirectional Text Messaging for Measurement and Motivation of Medication Adherence in Hypertension, a Pilot Study
A study testing Electronic Pill Bottle and Bidirectional Text Messaging in people with Hypertension, run by University of Pennsylvania.
Trial summary
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System practices and offered remote monitoring… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hypertension
- What is being tested?
- Electronic Pill Bottle and Bidirectional Text Messaging
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 150 participants
- Where
- No sites listed yet
- Study dates
- May 2016to 7 Nov 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Hypertension patients aged 18-75
- At least two clinic visits in the past 12 months
- Blood pressure readings in the last two visits that exceed recommended guidelines (150/90 or 140/90 if aged 21-59 yrs. or with diabetes or nondiabetic CKD).
- Cellular phone with text messaging capabilities
- Prescribed at least one medication for hypertension
Who cannot join
- Will not or cannot give consent
- Diagnosed with dementia, end stage renal disease, cirrhosis, or metastatic cancer
About this study
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System practices and offered remote monitoring with electronic pill bottles, bidirectional text messaging or usual care. Our aim is to analyze and compare the effects of remote monitoring with electronic pill bottles versus bidirectional messaging on blood pressure reduction after 4 months.
Read the detailed description
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System and offered remote monitoring with electronic pill bottles or bidirectional text messaging. Our aim is to analyze and compare the effects of remote monitoring with electronic pill bottles versus bidirectional messaging on blood pressure reduction after 4 months.
Patients will be randomized 2:2:1 to Arm A (electronic pill bottle), Arm B (bidirectional messaging), and Arm C (usual care). A total of 150 participants will be enrolled in the study, with 60 in each intervention arm and 30 in the control. After 4 months all patients will complete an in-person follow-up blood pressure measurement and end of program survey. We will monitor all patient's medical records for an additional 8 months after the intervention to track blood pressure measurement and number of outpatient visits.
Accrual: Participants in this study will be patients being treated within the UPHS health system. They will be identified via daily electronic medical records review by our study staff. The study staff will work with UPHS to create a filter for the electronic medical record system that will generate a monthly list of patients who may meet the study criteria. A study coordinator will review the list of patients to determine eligibility. If patients meet the minimal requirements they will be added to the study screening data base and contacted via recruitment letter and up to 3 follow-up phone calls. The intervention of the study will be 4 months from date of consent, and an additional 8 months of follow-up, passively monitoring visit utilization and blood pressure in the electronic medical record. After a patient enrolls a message will be sent to their PCP via EPIC to notify their physician that their patient is enrolled in our study. At the conclusion of the intervention, participants will complete an in-person blood pressure measurement and post-study survey. Information about BP measurements will be recorded in EPIC and message will be sent to the PCP with the research BP measurement included.
Analysis Plan: The primary outcome will be the systolic blood pressure during the 4 month visit, controlling for the initial systolic blood pressure. Additional outcomes include, percent that are normotensive, recruitment and attrition rates, and patient perceptions about intervention from survey. We will also track BP measurements from the EMR that is obtained through usual care as well as utilization of PCP visits, MPM messaging, and phone calls. We will also compare medication adherence between patients with the electron pill bottles and the patients with bidirectional messaging. Assuming 5.3mmHg standard deviation of SBP (given variability of BP over time) and a two-sided significance level of 0.017 (to accommodate the three pairwise comparisons), our sample size of 60 in each intervention arm and 30 in the control arm provides 80% power to detect a difference in SBP reduction of 3.75 mmHg between either intervention and usual care, and a difference in SBP reduction of 3.1 mmHg between the electronic pill bottle and bidirectional text messaging arms.
Data Safety: Paper-based records will be kept in a secure location and only be accessible to personnel involved in the study. Computer-based files will only be made available to personnel involved in the study through the use of access privileges and passwords.
Prior to access to any study-related information, personnel will be required to sign statements agreeing to protect the security and confidentiality of identifiable information.
Wherever feasible, identifiers will be removed from study-related information. Precautions are in place to ensure the data is secure by using passwords and encryption, because the research involves web-based surveys.
- Conditions
- Hypertension
- Being tested
- Electronic Pill Bottle, Bidirectional Text Messaging
- Keywords
- Automated Hovering, Remote Monitoring, Bidirectional Text Messaging
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electronic Pill BottleBehavioural
Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
Bidirectional Text MessagingBehavioural
Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
| Study group | Role | What they receive |
|---|---|---|
| Electronic Pill Bottle | Active comparator | Participants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication. Receives: Behavioral: Electronic Pill Bottle |
| Bidirectional Text Messaging | Active comparator | Participants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day. Receives: Behavioral: Bidirectional Text Messaging |
| Usual Care | No intervention | Participants in this arm do not receive a medication reminder system. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Systolic blood pressure
The primary outcome will be the systolic blood pressure during the 4 month in-person visit, controlling for the initial systolic blood pressure
Measured: after 4 month intervention
Secondary outcomes (2)
Medication Adherence
We will compare medication adherence between patients with the electronic pill bottles and the patients with bidirectional messaging.
Measured: 4 month intervention
Passive EMR monitoring
We will also track BP measurements from the EMR that is obtained through usual care as well as utilization of PCP visits, MPM messaging, and phone calls.
Measured: 12 months, including 4 months of intervention and 8 months after intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 May 2016 (estimated)
- Study startMay 2016
- Primary completion7 Jun 2017
- Study completion7 Nov 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HypertensionStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Care provider, Investigator
- Enrolment
- 150 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Shivan Mehta, MD, Principal investigator, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02778542
- Sponsor's protocol ID
- 824815
- Acronym
- Way2Text
- Status last verified
- Oct 2019
- First submitted
- 12 May 2016
- Last updated
- 4 Oct 2019
- Results posted
- No
Publications
Mehta SJ, Volpp KG, Troxel AB, Day SC, Lim R, Marcus N, Norton L, Anderson S, Asch DA. Electronic Pill Bottles or Bidirectional Text Messaging to Improve Hypertension Medication Adherence (Way 2 Text): a Randomized Clinical Trial. J Gen Intern Med. 2019 Nov;34(11):2397-2404. doi: 10.1007/s11606-019-05241-x. Epub 2019 Aug 8.
PubMed 31396815
Study at a glance
From the registry record, last updated by the sponsor on 4 Oct 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bidirectional Text Messaging for Measurement and Motivation of Medication Adherence in Hypertension, a Pilot Study
- ClinicalTrials.gov ID
- NCT02778542
- Acronym / sponsor ID
- Way2Text / 824815
- Conditions
- Hypertension
- Keywords
- Automated Hovering, Remote Monitoring, Bidirectional Text Messaging
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 150 participants (actual)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Study start
- May 2016 (actual)
- Primary completion
- 7 Jun 2017 (actual)
- Study completion
- 7 Nov 2017 (actual)
- First posted
- 20 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System practices and offered remote monitoring with electronic pill bottles, bidirectional text messaging or usual care. Our aim is to analyze and compare the effects of remote monitoring with electronic pill bottles versus bidirectional messaging on blood pressure reduction after 4 months.
Detailed description
The goal of this pilot study is to test different approaches to monitor medication adherence in hypertension patients, leveraging the NIH-funded Way to Health platform. Patients with poor blood pressure control will be recruited from the University of Pennsylvania Health System and offered remote monitoring with electronic pill bottles or bidirectional text messaging. Our aim is to analyze and compare the effects of remote monitoring with electronic pill bottles versus bidirectional messaging on blood pressure reduction after 4 months.
Patients will be randomized 2:2:1 to Arm A (electronic pill bottle), Arm B (bidirectional messaging), and Arm C (usual care). A total of 150 participants will be enrolled in the study, with 60 in each intervention arm and 30 in the control. After 4 months all patients will complete an in-person follow-up blood pressure measurement and end of program survey. We will monitor all patient's medical records for an additional 8 months after the intervention to track blood pressure measurement and number of outpatient visits.
Accrual: Participants in this study will be patients being treated within the UPHS health system. They will be identified via daily electronic medical records review by our study staff. The study staff will work with UPHS to create a filter for the electronic medical record system that will generate a monthly list of patients who may meet the study criteria. A study coordinator will review the list of patients to determine eligibility. If patients meet the minimal requirements they will be added to the study screening data base and contacted via recruitment letter and up to 3 follow-up phone calls. The intervention of the study will be 4 months from date of consent, and an additional 8 months of follow-up, passively monitoring visit utilization and blood pressure in the electronic medical record. After a patient enrolls a message will be sent to their PCP via EPIC to notify their physician that their patient is enrolled in our study. At the conclusion of the intervention, participants will complete an in-person blood pressure measurement and post-study survey. Information about BP measurements will be recorded in EPIC and message will be sent to the PCP with the research BP measurement included.
Analysis Plan: The primary outcome will be the systolic blood pressure during the 4 month visit, controlling for the initial systolic blood pressure. Additional outcomes include, percent that are normotensive, recruitment and attrition rates, and patient perceptions about intervention from survey. We will also track BP measurements from the EMR that is obtained through usual care as well as utilization of PCP visits, MPM messaging, and phone calls. We will also compare medication adherence between patients with the electron pill bottles and the patients with bidirectional messaging. Assuming 5.3mmHg standard deviation of SBP (given variability of BP over time) and a two-sided significance level of 0.017 (to accommodate the three pairwise comparisons), our sample size of 60 in each intervention arm and 30 in the control arm provides 80% power to detect a difference in SBP reduction of 3.75 mmHg between either intervention and usual care, and a difference in SBP reduction of 3.1 mmHg between the electronic pill bottle and bidirectional text messaging arms.
Data Safety: Paper-based records will be kept in a secure location and only be accessible to personnel involved in the study. Computer-based files will only be made available to personnel involved in the study through the use of access privileges and passwords.
Prior to access to any study-related information, personnel will be required to sign statements agreeing to protect the security and confidentiality of identifiable information.
Wherever feasible, identifiers will be removed from study-related information. Precautions are in place to ensure the data is secure by using passwords and encryption, because the research involves web-based surveys.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Electronic Pill Bottle | Active comparator | Behavioral: Electronic Pill BottleParticipants will be mailed an electronic pill bottle for their blood pressure medication.These pill bottles will track how often the participant opens the bottle to take their medication and will transmit that information to study team via cellular data. Participants will also receive a daily text message reminder to take your blood pressure medication. |
| Bidirectional Text Messaging | Active comparator | Behavioral: Bidirectional Text MessagingParticipants assigned to bi-directional texting, will receive a daily text message reminder to take their blood pressure medication. Patients in this arm are expected to send a response to the reminder message, indicating if they took their medication that day. |
| Usual Care | No intervention | –Participants in this arm do not receive a medication reminder system. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Hypertension patients aged 18-75
- At least two clinic visits in the past 12 months
- Blood pressure readings in the last two visits that exceed recommended guidelines (150/90 or 140/90 if aged 21-59 yrs. or with diabetes or nondiabetic CKD).
- Cellular phone with text messaging capabilities
- Prescribed at least one medication for hypertension
Key exclusion criteria (2 listed)
- Will not or cannot give consent
- Diagnosed with dementia, end stage renal disease, cirrhosis, or metastatic cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electronic Pill BottlePatients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication. | Behavioural | Electronic Pill Bottle |
| Bidirectional Text MessagingPatients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily. | Behavioural | Bidirectional Text Messaging |
Primary outcome
Systolic blood pressure
Time frame: after 4 month intervention
The primary outcome will be the systolic blood pressure during the 4 month in-person visit, controlling for the initial systolic blood pressure
2 secondary outcomes
Medication Adherence
Time frame: 4 month intervention
Passive EMR monitoring
Time frame: 12 months, including 4 months of intervention and 8 months after intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Oct 2019.
- Derived from this study: PubMed 31396815Mehta SJ, Volpp KG, Troxel AB, Day SC, Lim R, Marcus N, Norton L, Anderson S, Asch DA. Electronic Pill Bottles or Bidirectional Text Messaging to Improve Hypertension Medication Adherence (Way 2 Text): a Randomized Clinical Trial. J Gen Intern Med. 2019 Nov;34(11):2397-2404. doi: 10.1007/s11606-019-05241-x. Epub 2019 Aug 8.
Related trials for Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Shivan Mehta, MD principal investigator
University of Pennsylvania
Questions about this trial
What is this clinical trial studying?
A study testing Electronic Pill Bottle and Bidirectional Text Messaging in people with Hypertension, run by University of Pennsylvania.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Oct 2019. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Systolic blood pressure (time frame: after 4 month intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02778542, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Oct 2019.